Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A new diagnostic footprint in China
January 2017
SHARING OPTIONS:

CAMBRIDGE, U.K.—Horizon Discovery Group plc is looking eastward with the announcement of partnerships with three leading Chinese diagnostic kit developers, under which it will provide HDx Reference Standards for novel next-generation sequencing (NGS) assay development, clinical trials and inclusion as in-kit controls under Original Equipment Manufacturer (OEM) agreements. Under the auspices of these deals, Horizon will support the development of new NGS diagnostic assays that, pending regulatory approval, can be used to identify patients who would benefit from novel targeted therapies to treat solid and liquid tumors. Horizon will receive payment for reference standards for use as quality controls in the companies’ assay development and clinical trial programs. Horizon expects that each partner will develop between three and four assays per year over the next several years, with Horizon providing reference standards for each, and the first assays are expected to be approved in 2018.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.